# NCT03618550 (NCT03618550)

> Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus GVD
- Indication: relapsed or refractory classical Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03618550
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Hodgkin Lymphoma; Relapsed or Refractory Hodgkin Lymphoma
- Interventions: pembrolizumab; gemcitabine; vinorelbine; liposomal doxorubicin; Stem cell mobilization and collection; Involved-site radiation therapy
- Enrollment: 257
- Primary outcome: Complete response rate (part 1)
- Primary outcome: Assess freedom from disease at 5 years (part 3)

## Indexed commentary on NCT03618550 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03618550